Table 1.
Baseline characteristics of patients by infection group
| HIV monoinfected patients (n = 134) | HBV or HCV coinfected patients (n = 35) | p | |||
|---|---|---|---|---|---|
| Women (no.) | 91 | (68%) | 22 | (63%) | 0.6 |
| Age (years) | |||||
| Median (IQR) | 34.5 | (28.4-39.7) | 41.6 | (33.7-48.8) | <0.001 |
| <42 (no.) | 113 | (84%) | 19 | (54%) | <0.001 |
| Time since diagnosis of HIV seropositivity (months) | |||||
| Median (IQR) | 29.4 | (13.5-53.4) | 22.1 | (8.3-43.6) | 0.2 |
| <24 (no.) | 56 | (42%) | 18 | (51%) | 0.3 |
| Body weight (Kg) [median (IQR)] | 65 | (55-70) | 63 | (54-70) | 0.7 |
| Body mass index (Kg/m2)* | |||||
| median (IQR) | 23.2 | (21.6-24.7) | 22.2 | (20.6-25.6) | 0.2 |
| ≥ 21 (no.) | 108 | (82%) | 25 | (74%) | 0.3 |
| Karnofsky score >90% (no.) | 72 | (54%) | 15 | (43%) | 0.3 |
| CDC clinical stage (no.) | 0.7 | ||||
| A | 19 | (14%) | 4 | (11%) | |
| B | 58 | (43%) | 13 | (37%) | |
| C | 57 | (43%) | 18 | (51%) | |
| CD4 cell count (/mm3) | |||||
| Median (IQR) | 138 | (67-222) | 135 | (68-216) | 0.7 |
| <100 (no.) | 80 | (60%) | 22 | (63%) | 0.7 |
| HIV-1 viral load (log10 copies/mL)† | |||||
| Median (IQR) | 5.3 | (4.7-5.5) | 5.3 | (4.8-5.7) | 0.5 |
| <5.0 (no.) | 50 | (37%) | 11 | (31%) | 0.5 |
| Hemoglobin (g/dL) | |||||
| Median (IQR) | 11.0 | (9.8-12.1) | 11.1 | (9.8-12.9) | 0.6 |
| <10 (no.) | 36 | (27%) | 10 | (29%) | 0.8 |
| Total lymphocyte count (/mm3) | |||||
| Median (IQR) | 1578 | (1080-2100) | 1408 | (1000-1900) | 0.4 |
| <1700 (no.) | 77 | (57%) | 23 | (66%) | 0.4 |
| ALT level (×ULN) | |||||
| Median (IQR) | 0.6 | (0.4-0.7) | 0.8 | (0.6-1.2) | <0.001 |
| ≥ 1.25 (no.) | 8 | (6%) | 8 | (30%) | 0.002 |
| ASAT (×ULN)‡ | |||||
| Median (IQR) | 0.8 | (0.6-1.1) | 1.3 | (0.9-1.7) | <0.001 |
| ≥ 1.25 (no.) | 21 | (17%) | 17 | (52%) | <0.001 |
| History of antiretroviral treatment (no.) | 0.6 | ||||
| None | 131 | (98%) | 34 | (97%) | |
| HAART | 1 | (1%) | 1 | (3%) | |
| Nevirapine (PMTCT) | 2 | (2%) | 0 | - | |
| Baseline antiretroviral treatment (no.) | 0.3 | ||||
| Zidovudine+lamivudine+nevirapine | 70 | (52%) | 15 | (43%) | |
| Stavudine+lamivudine+nevirapine | 64 | (48%) | 20 | (57%) | |
| Cotrimoxazole prophylaxis (no.) | 124 | (93%) | 35 | (100%) | 0.1 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; PMTCT, prevention of mother-to-child transmission; HAART, highly active antiretroviral therapy
* 3 missing values; † 1 missing value; ‡ 9 missing values